Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Washetine, Kevin; Heeke, Simon; Bonnetaud, Christelle; Kara-Borni, Mehdi; Ilié, Marius; Lassalle, Sandra; Butori, Catherine; Long‐Mira, Elodie; Marquette, Charles Hugo; Cohen, Charlotte; Mouroux, Jérôme; Selva, Éric; Tanga, Virginie; Bence, Coraline; Félix, Jean-Marc; Gazoppi, Loïc; Skhiri, Taycir; Gormally, Emmanuelle; Boucher, Pascal; Clément, Bruno; Dagher, Georges; Hofman, Véronique; Hofman, Paul

doi:10.3390/cancers10070220

Cited by 15 publications

(14 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since 2015, OncoAge has been associated with the publication of 86 scientific articles referenced in NCBI PubMed (the “FHU OncoAge” was listed with the author’s affiliation). For example, some publications are related to epidemiological, clinical, and translational research projects made in lung cancer and COPD, such as lung cancer screening and assessment of biomarkers [37,38,39,40,41,42,43,44,45,46]. Recently, a new project was accomplished by physicians from the Nice University Hospital and researchers belonging to the “Institut National de Recherche en Informatique et en Automatique” (Inria) who aimed to develop a lung cancer screening program based on the integration of three signatures: clinical data (leading to better risk factor assessment), chest low dose CT scan (by using computer-aided diagnosis), and biological blood signatures [47].…”

Section: Oncoage: Main Results After Three Years Of Existence (201mentioning

confidence: 99%

The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again

Hofman

Ayache

Barbry

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

It is generally accepted that carcinogenesis and aging are two biological processes, which are known to be associated. Notably, the frequency of certain cancers (including lung cancer), increases significantly with the age of patients and there is now a wealth of data showing that multiple mechanisms leading to malignant transformation and to aging are interconnected, defining the so-called common biology of aging and cancer. OncoAge, a consortium launched in 2015, brings together the multidisciplinary expertise of leading public hospital services and academic laboratories to foster the transfer of scientific knowledge rapidly acquired in the fields of cancer biology and aging into innovative medical practice and silver economy development. This is achieved through the development of shared technical platforms (for research on genome stability, (epi)genetics, biobanking, immunology, metabolism, and artificial intelligence), clinical research projects, clinical trials, and education. OncoAge focuses mainly on two pilot pathologies, which benefit from the expertise of several members, namely lung and head and neck cancers. This review outlines the broad strategic directions and key advances of OncoAge and summarizes some of the issues faced by this consortium, as well as the short- and long-term perspectives.

show abstract

Section: Oncoage: Main Results After Three Years Of Existence (201mentioning

confidence: 99%

The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again

Hofman

Ayache

Barbry

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“… 33 Conversely, a number of the pathology laboratories included in the present work had the possibility to participate in and/or lead research projects into COVID-19. 33 , 34 , 35 , 36 , 37 Thus, at the time of submission of this study, 71 manuscripts were published or submitted for publication in association with one or several of these pathology laboratories, which was a fruitful consequence occurring in only a short period of time.…”

Section: Discussionmentioning

confidence: 99%

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

Hofman¹,

Ilié²,

Chamorey³

et al. 2021

ESMO Open

View full text Add to dashboard Cite

“…China Kadoorie Biobank and UK Biobank are good examples of this type of biobank [ 37 , 38 ]. Other biobanks focus on a specific disease such as the French glioblastoma biobank, the β -thalassemia biobank, chronic kidney disease biobank, and lung cancer biobank, and these types of biobanks are called patient-based biobank or disease-oriented biobank [ 5 , 7 , 39 – 55 ]. Other biobanks collect samples from patients with different diseases such as the Lausanne institutional biobank and the Japanese biobank [ 56 , 57 ].…”

Section: Discussionmentioning

confidence: 99%

Morocco’s First Biobank: Establishment, Ethical Issues, Biomedical Research Opportunities, and Challenges

Lhousni

Belmokhtar

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Biobanks are highly organized infrastructures that allow the storage of human biological specimens associated with donors’ personal and clinical data. These infrastructures play a key role in the development of translational medical research. In this context, we launched, in November 2015, the first biobank in Morocco (BRO Biobank) in order to promote biomedical research and provide opportunities to include Moroccan and North African ethnic groups in international biomedical studies. Here, we present the setup and the sample characteristics of BRO Biobank. Methods. Patients were recruited at several departments of two major health-care centers in the city of Oujda. Healthy donors were enrolled during blood donation campaigns all over Eastern Morocco. From each participant, personal, clinical, and biomedical data were collected, and several biospecimens were stored. Standard operating procedures have been established in accordance with international guidelines on human biobanks. Results. Between November 2015 and July 2020, 2446 participants were recruited into the BRO Biobank, of whom 2013 were healthy donors, and 433 were patients. For healthy donors, the median age was 35 years with a range between 18 and 65 years and the consanguinity rate was 28.96%. For patients, the median age was 11 years with a range between 1 day and 83 years. Among these patients, 55% had rare diseases (hemoglobinopathies, intellectual disabilities, disorders of sex differentiation, myopathies, etc.), 13% had lung cancer, 4% suffered from hematological neoplasms, 3% were from the kidney transplantation project, and 25% had unknown diagnoses. The BRO Biobank has collected 5092 biospecimens, including blood, white blood cells, plasma, serum, urine, frozen tissue, FFPE tissue, and nucleic acids. A sample quality control has been implemented and suggested that samples of the BRO Biobank are of high quality and therefore suitable for high-throughput nucleic acid analysis. Conclusions. The BRO Biobank is the largest sample collection in Morocco, and it is ready to provide samples to national and international research projects. Therefore, the BRO Biobank is a valuable resource for advancing translational medical research.

show abstract

Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Cited by 15 publications

References 76 publications

The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again

The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

Morocco’s First Biobank: Establishment, Ethical Issues, Biomedical Research Opportunities, and Challenges

Contact Info

Product

Resources

About